Patients are waiting for novel therapies like ATMPs, bacteriophages, and mRNA-based options. To deliver these life-changing treatments, you need the agility to switch between different batches and therapies quickly. Automating the aseptic filling process in gloveless isolators shortens these changeover times.
With precious therapies like personalized medicines, reducing contamination risk is essential. Gloveless, robotic aseptic filling workcells from Cytiva remove the human operator from the process, therefore eliminating one of the greatest sources of contamination and maintaining drug product quality.
Build your filling facility
Some companies believe outsourcing the filling step to a contract development and manufacturing organization (CDMO) is the only viable option. You might be surprised at how quickly you can build your own capabilities, so you can maintain control of your whole advanced therapy manufacturing process.